Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer
Research type
Research Study
Full title
RESPECT: Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study
IRAS ID
186474
Contact name
Andreas Makris
Contact email
Sponsor organisation
East and North Hertfordshire NHS Trust
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
RD2015-64, Mount Vernon Breast Cancer Research Unit Clinical Trials Website
Duration of Study in the UK
1 years, 11 months, 28 days
Research summary
To evaluate whether whole body MRI (WB-MRI) allows an earlier identification of progression in the bone in comparison to CT scans in patients with bone metastasis from breast cancer. \nThis trial is a feasibility study prior to a planned phase III trial.\nCurrently, assessing response to treatment of metastatic breast cancer in the bone is limited by the technical problems associated with CT scans and bone scans. WB-MRI provides theoretical and practical advantages that allow for more detailed analysis of disease response or progression. This may allow for earlier identification of progressive disease and earlier change in treatment. \nParticipants in the study will have a CT scan, bone scan and WB-MRI at baseline and then repeated CT and WB-MRI scans every 12 weeks (until week 96, and then every 24 weeks) until there is evidence of progressive disease on either of the imaging modalities. At the point of disease progression, a repeat bone scan is performed and the involvement of the patient in the trial comes to an end.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
15/EE/0468
Date of REC Opinion
4 Feb 2016
REC opinion
Further Information Favourable Opinion